Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Abbisko Cayman Limited ( (HK:2256) ).
Abbisko Therapeutics has announced the successful dosing of the first patient in a Phase II clinical study for ABSK061, a selective FGFR2/3 inhibitor, aimed at treating achondroplasia in children. This development marks a significant step in addressing the genetic disorder, which affects growth in children, by potentially offering a more effective treatment option with fewer side effects compared to existing therapies.
The most recent analyst rating on (HK:2256) stock is a Hold with a HK$15.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.
More about Abbisko Cayman Limited
Abbisko Therapeutics Co., Ltd. is a Shanghai-based biopharmaceutical company focused on oncology. Established in 2016, it aims to develop innovative medicines for unmet medical needs in China and globally, with a strong emphasis on precision oncology and immuno-oncology.
Average Trading Volume: 3,160,436
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.74B
See more insights into 2256 stock on TipRanks’ Stock Analysis page.